Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Effects of beta-blocker therapy on mortality in patients with heart failure
A systematic overview of randomized controlled trials
Clinical Trials Research Unit, Department of Medicine, Faculty of Medicine and Health Science, The University of Auckland Auckland, New Zealand
Received 4 December 1996; accepted 12 December 1996.
Correspondence: Dr Robert Doughty, Department of Medicine, The University of Auckland, Private Bag 92019, Auckland, New Zealand
Abstract
AIMS: Several randomized trials have reported that beta-blocker therapy improves left ventricular function and reduces the rate of hospitalization in patients with congestive heart failure. However, most trials were individually too small to assess reliably the effects of treatment on mortality. In these circumstances a systematic overview of all trials of beta-blocker therapy in patients with congestive heart failure may provide the most reliable guide to treatment effects.
METHODS AND RESULTS: Details were sought from all completed randomized trials of oral beta-blocker therapy in patients with heart failure of any aetiology. In particular, data on mortality were sought from all randomized patients for the scheduled treatment period. The typical effect of treatment on mortality was estimated from an overview in which the results of all individual trials were combined using standard statistical methods. Twenty-four randomized trials, involving 3141 patients with stable congestive heart failure were identified. Complete data on mortality were obtained from all studies, and a total of 297 deaths were documented during an average of 13 months of follow-up. Overall, there was a 31% reduction in the odds of death among patients assigned a beta-blocker (95% confidence interval 11 to 46%, 2P=0·0035), representing an absolute reduction in mean annual mortality from 9·7% to 7·5%. The effects on mortality of vasodilating beta-blockers (47% reduction SD 15), principally carvedilol, were nonsignificantly greater (2P=0·09) than those of standard agents (18% reduction SD 15), principally metoprolol.
CONCLUSION: Beta-blocker therapy is likely to reduce mortality in patients with heart failure. However, large-scale, long-term randomized trials are still required to confirm and quantify more precisely the benefit suggested by this overview.
Key Words: Meta-analysis • beta-adrenergic antagonists • survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Le Corvoisier, L. Hittinger, P. Chanson, O. Montagne, I. Macquin-Mavier, and P. Maison Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egred, S. Shaw, B. Mohammad, P. Waitt, and E. Rodrigues Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease QJM, July 1, 2005; 98(7): 493 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S Hillis and P. Bloomfield Basic transthoracic echocardiography BMJ, June 18, 2005; 330(7505): 1432 - 1436. [Full Text] [PDF]
|
|
|
|
 |
|
 D J Fox, M Kibiro, J Eichhofer, and N P Curzen Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Postgrad. Med. J., June 1, 2005; 81(956): 401 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Boutitie, C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers Relationship Between Stroke Relative Risk and Change in Systolic Blood Pressure: The Misuse of Meta-Regression * Response Stroke, October 1, 2004; 35(10): 2237 - 2238. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Johnson, Y. Jin, H. Quan, and B. Cujec Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1438 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Taniguchi, K. Ueshima, I. Chiba, I. Segawa, N. Kobayashi, M. Saito, and K. Hiramori A New Method Using Pulmonary Gas-Exchange Kinetics To Evaluate Efficacy of {beta}-Blocking Agents in Patients With Dilated Cardiomyopathy Chest, September 1, 2003; 124(3): 954 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. C. ten Broecke, S. G. De Hert, E. Mertens, and H. F. Adriaensen Effect of preoperative {beta}-blockade on perioperative mortality in coronary surgery Br. J. Anaesth., January 1, 2003; 90(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardioselective {beta}-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis Ann Intern Med, November 5, 2002; 137(9): 715 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Fonarow Quality Indicators for the Management of Heart Failure in Vulnerable Elders Ann Intern Med, October 16, 2001; 135(8_Part_2): 694 - 702. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Camm and Y. G. Yap Clinical Trials of Antiarrhythmic Drugs in Postmyocardial Infarction and Congestive Heart Failure Patients Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 99 - 106. [PDF]
|
|
|
|
|
|
A. Mortara, M. T. La Rovere, G. D. Pinna, R. Maestri, S. Capomolla, and F. Cobelli Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1612 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Fagerberg The merit of beta1-blockade in heart failure Eur. Heart J., December 2, 1999; 20(24): 1761 - 1763. [PDF]
|
|
|
|
|
|
S.A. Cook and P.A. Poole-Wilson Cardiac myocyte apoptosis Eur. Heart J., November 2, 1999; 20(22): 1619 - 1629. [PDF]
|
|
|
|
|
|
B.A. Bart, G. Ertl, P. Held, J. Kuch, A.P. Maggioni, J. McMurray, E.L. Michelson, J.L. Rouleau, L. Warner Stevenson, K. Swedberg, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry Eur. Heart J., August 2, 1999; 20(16): 1182 - 1190. [Abstract] [PDF]
|
|
|
|
|
|
G. Guyatt A 75-Year-Old Man With Congestive Heart Failure JAMA, June 23, 1999; 281(24): 2321 - 2328. [Full Text] [PDF]
|
|
|
|
|
|
D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 916 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Macdonald, A. M. Keogh, C. L. Aboyoun, M. Lund, R. Amor, and D. J. McCaffrey Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure J. Am. Coll. Cardiol., March 15, 1999; 33(4): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Smith, G. E. Reiber, B. M. Psaty, S. R. Heckbert, D. S. Siscovick, J. L. Ritchie, N. R. Every, and T. D. Koepsell Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1305 - 1311. [Abstract] [Full Text] [PDF]
|
|